Celldex Therapeutics, Inc.
celldex.comWhat Do They Do?
Develops therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune and other diseases.
10-K for FY2025, filed Feb 25, 2026Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to…View ↗
How Do They Make Money?
Rockefeller University pays for manufacturing and research and development services on a time-and-materials or negotiated fixed-price basis; some services are billed in advance and earned as the work is performed. Collaborative agreements can also provide signing and licensing fees, research funding, milestones and royalties.
10-K for FY2025, filed Feb 25, 2026The Company has entered into agreements with Rockefeller University (“Rockefeller”) pursuant to which the Company performs manufacturing…View ↗
At December 31, 2025, the Company had $1.8 million in contract liabilities recorded, representing consideration billed in advance of…View ↗
Revenue for the Company is derived from product development agreements with collaborative partners for the research and development of…View ↗
-
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗
$1.5M
-
10-K for FY2025, filed Feb 25, 2026
$1.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product development and licensing agreements
Mix
|
6.3%
FY2022: 2.4%
|
Product development and licensing agreements, FY2025
$97K Sources
|
Mix |
|
Contracts and grants
Recurring
10-K for FY2025, filed Feb 25, 2026 |
94%
FY2022: 98%
|
Contracts and grants, FY2025
$1.4M Sources
|
Recurring |
Who Are Their Customers?
Collaborative partners contract with Celldex for research and development of drug candidates; Rockefeller University contracts for manufacturing and research services.
10-K for FY2025, filed Feb 25, 2026
Do Revenues Turn Into Profits?
No. It lost $258.8M in FY2025.
10-K for FY2025, filed Feb 25, 2026
−$287.4MView ↗
10-K for FY2025, filed Feb 25, 2026
−$258.8MView ↗
10-K for FY2025, filed Feb 25, 2026
−$213.6MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$73.5MView ↗
- ▲ +30% (Loss)
- vs −$56.6M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Jul 15, 2026
The CFO plans to retire
Sam Martin plans to retire effective on or about March 31, 2027; the company has started a search for a successor.
Sources
8-K, filed Jul 15, 2026
On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the…View ↗
Shrinking. Revenue fell 67% in 4 years, from $4.7M in FY2021 to $1.5M in FY2025, about 24% a year.
Bispecific platform focus
The earlier report described the platform as targeting inflammatory diseases and tumor immunity; the latest report describes candidate selection and development focused on inflammatory diseases.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026Our next generation bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and…View ↗
Our next generation bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases.…View ↗
Who Do They Compete With?
Competes with Abbvie, Akeso Bio, Amgen/Kiowa Kirin, Celltrion, Eli Lilly, Galderma/Chugai, Genentech/Novartis, Incyte, Kashiv Biosciences, Leo Pharma, Medimetriks, Novartis, Pfizer, Regeneron/Sanofi, Sanofi, Teva, and Vanda Pharmaceuticals
10-K for FY2025, filed Feb 25, 2026AbbvieView ↗
Loading...
